Jafron Total Liab vs Accounts Payable Analysis

300529 Stock

29.86 0.52 1.71%

Jafron Biomedical financial indicator trend analysis is infinitely more than just investigating Jafron Biomedical recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jafron Biomedical is a good investment. Please check the relationship between Jafron Biomedical Total Liab and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jafron Biomedical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Total Liab vs Accounts Payable

Total Liab vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jafron Biomedical Total Liab account and Accounts Payable. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Jafron Biomedical's Total Liab and Accounts Payable is 0.97. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Jafron Biomedical Co, assuming nothing else is changed. The correlation between historical values of Jafron Biomedical's Total Liab and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Jafron Biomedical Co are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Liab i.e., Jafron Biomedical's Total Liab and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.97

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Accounts Payable

An accounting item on the balance sheet that represents Jafron Biomedical obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Jafron Biomedical are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Jafron Biomedical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jafron Biomedical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jafron Biomedical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

The current year's Tax Provision is expected to grow to about 119.8 M, whereas Selling General Administrative is forecasted to decline to about 363.6 M.

	2021	2022	2023	2024 (projected)
Operating Income	1.4B	1.0B	523.2M	528.6M
Total Revenue	2.7B	2.5B	1.9B	1.2B

Operating Income Total Revenue

Jafron Biomedical fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Retained Earnings	Accounts Payable	Cash	Other Assets	Net Receivables	Inventory	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Good Will	Net Tangible Assets	Deferred Long Term Liab	Total Current Assets	Non Current Assets Total	Non Currrent Assets Other	Short Term Investments	Non Current Liabilities Total	Common Stock Shares Outstanding	Net Invested Capital
Total Assets		-0.03	0.96	0.89	0.97	0.89	0.95	1.0	0.98	0.71	0.95	0.61	0.94	0.88	0.95	0.99	0.49	0.92	0.97	0.95	0.95	0.87	0.81	0.91	0.68	0.94
Other Current Liab	-0.03		-0.13	0.24	-0.1	0.2	-0.27	0.0	0.02	0.47	-0.31	0.42	-0.28	0.14	0.05	-0.04	0.66	0.15	-0.18	0.07	-0.05	0.34	0.45	-0.35	-0.28	-0.16
Total Current Liabilities	0.96	-0.13		0.78	0.95	0.76	0.98	0.96	0.96	0.51	0.98	0.4	0.97	0.77	0.9	0.95	0.32	0.82	0.93	0.87	0.89	0.79	0.77	0.92	0.74	0.88
Total Stockholder Equity	0.89	0.24	0.78		0.82	0.99	0.75	0.88	0.84	0.86	0.74	0.76	0.71	0.96	0.87	0.88	0.74	0.98	0.82	0.97	0.93	0.89	0.88	0.66	0.3	0.89
Other Liab	0.97	-0.1	0.95	0.82		0.83	0.94	0.97	0.97	0.65	0.95	0.52	0.96	0.82	0.92	0.98	0.38	0.85	0.96	0.9	0.91	0.84	0.74	0.94	0.7	0.92
Retained Earnings	0.89	0.2	0.76	0.99	0.83		0.74	0.87	0.85	0.85	0.75	0.8	0.73	0.98	0.85	0.88	0.72	0.98	0.85	0.97	0.95	0.89	0.85	0.69	0.31	0.92
Accounts Payable	0.95	-0.27	0.98	0.75	0.94	0.74		0.94	0.92	0.48	0.99	0.37	0.97	0.76	0.89	0.94	0.25	0.8	0.93	0.85	0.89	0.73	0.68	0.94	0.74	0.89
Cash	1.0	0.0	0.96	0.88	0.97	0.87	0.94		0.98	0.69	0.95	0.58	0.94	0.86	0.94	0.99	0.47	0.91	0.96	0.94	0.93	0.87	0.82	0.9	0.69	0.92
Other Assets	0.98	0.02	0.96	0.84	0.97	0.85	0.92	0.98		0.68	0.93	0.55	0.95	0.84	0.89	0.96	0.47	0.88	0.95	0.92	0.92	0.91	0.83	0.92	0.68	0.91
Net Receivables	0.71	0.47	0.51	0.86	0.65	0.85	0.48	0.69	0.68		0.47	0.86	0.47	0.78	0.7	0.69	0.85	0.77	0.61	0.78	0.69	0.86	0.71	0.43	0.24	0.67
Inventory	0.95	-0.31	0.98	0.74	0.95	0.75	0.99	0.95	0.93	0.47		0.38	0.99	0.76	0.87	0.94	0.23	0.8	0.96	0.86	0.89	0.73	0.66	0.97	0.75	0.91
Other Current Assets	0.61	0.42	0.4	0.76	0.52	0.8	0.37	0.58	0.55	0.86	0.38		0.38	0.78	0.65	0.63	0.77	0.7	0.59	0.66	0.62	0.67	0.58	0.35	0.22	0.61
Total Liab	0.94	-0.28	0.97	0.71	0.96	0.73	0.97	0.94	0.95	0.47	0.99	0.38		0.74	0.86	0.94	0.2	0.78	0.96	0.85	0.88	0.75	0.65	0.99	0.76	0.9
Intangible Assets	0.88	0.14	0.77	0.96	0.82	0.98	0.76	0.86	0.84	0.78	0.76	0.78	0.74		0.85	0.88	0.68	0.97	0.86	0.96	0.96	0.85	0.83	0.7	0.31	0.93
Common Stock	0.95	0.05	0.9	0.87	0.92	0.85	0.89	0.94	0.89	0.7	0.87	0.65	0.86	0.85		0.96	0.47	0.88	0.89	0.89	0.87	0.78	0.77	0.81	0.64	0.86
Property Plant Equipment	0.99	-0.04	0.95	0.88	0.98	0.88	0.94	0.99	0.96	0.69	0.94	0.63	0.94	0.88	0.96		0.47	0.91	0.98	0.93	0.94	0.84	0.78	0.91	0.69	0.93
Good Will	0.49	0.66	0.32	0.74	0.38	0.72	0.25	0.47	0.47	0.85	0.23	0.77	0.2	0.68	0.47	0.47		0.65	0.37	0.59	0.53	0.71	0.71	0.13	0.0	0.45
Net Tangible Assets	0.92	0.15	0.82	0.98	0.85	0.98	0.8	0.91	0.88	0.77	0.8	0.7	0.78	0.97	0.88	0.91	0.65		0.86	0.98	0.97	0.87	0.89	0.74	0.34	0.93
Deferred Long Term Liab	0.97	-0.18	0.93	0.82	0.96	0.85	0.93	0.96	0.95	0.61	0.96	0.59	0.96	0.86	0.89	0.98	0.37	0.86		0.91	0.93	0.79	0.7	0.94	0.71	0.95
Total Current Assets	0.95	0.07	0.87	0.97	0.9	0.97	0.85	0.94	0.92	0.78	0.86	0.66	0.85	0.96	0.89	0.93	0.59	0.98	0.91		0.98	0.9	0.85	0.81	0.43	0.96
Non Current Assets Total	0.95	-0.05	0.89	0.93	0.91	0.95	0.89	0.93	0.92	0.69	0.89	0.62	0.88	0.96	0.87	0.94	0.53	0.97	0.93	0.98		0.86	0.82	0.85	0.45	0.99
Non Currrent Assets Other	0.87	0.34	0.79	0.89	0.84	0.89	0.73	0.87	0.91	0.86	0.73	0.67	0.75	0.85	0.78	0.84	0.71	0.87	0.79	0.9	0.86		0.89	0.7	0.42	0.82
Short Term Investments	0.81	0.45	0.77	0.88	0.74	0.85	0.68	0.82	0.83	0.71	0.66	0.58	0.65	0.83	0.77	0.78	0.71	0.89	0.7	0.85	0.82	0.89		0.58	0.3	0.73
Non Current Liabilities Total	0.91	-0.35	0.92	0.66	0.94	0.69	0.94	0.9	0.92	0.43	0.97	0.35	0.99	0.7	0.81	0.91	0.13	0.74	0.94	0.81	0.85	0.7	0.58		0.76	0.89
Common Stock Shares Outstanding	0.68	-0.28	0.74	0.3	0.7	0.31	0.74	0.69	0.68	0.24	0.75	0.22	0.76	0.31	0.64	0.69	0.0	0.34	0.71	0.43	0.45	0.42	0.3	0.76		0.49
Net Invested Capital	0.94	-0.16	0.88	0.89	0.92	0.92	0.89	0.92	0.91	0.67	0.91	0.61	0.9	0.93	0.86	0.93	0.45	0.93	0.95	0.96	0.99	0.82	0.73	0.89	0.49

Click cells to compare fundamentals

Jafron Biomedical Account Relationship Matchups

Jafron Biomedical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.5B	3.2B	4.8B	5.4B	5.5B	5.8B
Other Current Liab	131.8M	140.8M	129.3M	5.5M	4.9M	4.6M
Total Current Liabilities	262.6M	330.8M	386.3M	717.2M	829.4M	870.9M
Total Stockholder Equity	2.1B	2.8B	3.4B	3.6B	3.1B	1.8B
Other Liab	51.1M	61.5M	52.2M	125.8M	144.7M	151.9M
Retained Earnings	1.2B	1.7B	2.3B	2.1B	2.0B	1.0B
Accounts Payable	32.8M	50.2M	60.8M	128.5M	135.6M	142.4M
Cash	1.3B	1.6B	2.3B	2.6B	2.8B	3.0B
Other Assets	107.9M	102.4M	91.6M	225.4M	259.2M	272.2M
Net Receivables	169.8M	167.4M	314.4M	221.7M	74.9M	118.9M
Inventory	92.3M	120.7M	196.5M	349.1M	385.0M	404.2M
Other Current Assets	25.9M	65.3M	75.3M	35.6M	17.3M	26.1M
Total Liab	324.1M	383.1M	1.4B	1.8B	2.4B	2.5B
Intangible Assets	48.1M	89.9M	101.3M	100.4M	100.4M	53.5M
Common Stock	417.3M	418.7M	799.1M	805.5M	926.3M	972.6M
Property Plant Equipment	457.6M	639.6M	905.5M	1.3B	1.5B	1.5B
Net Tangible Assets	1.6B	2.1B	2.7B	3.2B	3.7B	2.0B
Deferred Long Term Liab	3.4M	14.8M	20.4M	36.0M	41.3M	43.4M
Total Current Assets	1.6B	2.0B	3.1B	3.3B	3.3B	2.1B
Non Current Assets Total	934.9M	1.2B	1.8B	2.1B	2.2B	1.3B
Non Currrent Assets Other	77.5M	58.2M	162.8M	148.2M	107.0M	102.3M
Non Current Liabilities Total	61.5M	52.2M	1.0B	1.1B	1.6B	1.6B
Common Stock Shares Outstanding	795.5M	799.1M	805.5M	807.7M	807.6M	880.0M
Net Invested Capital	2.1B	2.8B	4.3B	4.8B	4.8B	3.4B
Net Working Capital	1.3B	1.7B	2.7B	2.6B	2.5B	2.0B
Capital Stock	418.7M	799.1M	805.5M	807.7M	807.6M	743.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Other Information on Investing in Jafron Stock

Balance Sheet is a snapshot of the financial position of Jafron Biomedical at a specified time, usually calculated after every quarter, six months, or one year. Jafron Biomedical Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Jafron Biomedical and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Jafron currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jafron Total Liab vs Accounts Payable Analysis

Total Liab vs Accounts Payable

Total Liab vs Accounts Payable Correlation Analysis

Correlation Coefficient

Total Liab

Accounts Payable

Jafron Biomedical fundamental ratios Correlations

Jafron Biomedical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Jafron Biomedical fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Jafron Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Property Plant Equipment	+ 0.99	Total Assets
Retained Earnings	+ 0.99	Total Stockholder Equity
Inventory	+ 0.99	Accounts Payable
Property Plant Equipment	+ 0.99	Cash
Total Liab	+ 0.99	Inventory

Non Current Liabilities Total	- 0.35	Other Current Liab
Inventory	- 0.31	Other Current Liab
Common Stock Shares Outstanding	- 0.28	Other Current Liab
Total Liab	- 0.28	Other Current Liab
Accounts Payable	- 0.27	Other Current Liab
Deferred Long Term Liab	- 0.18	Other Current Liab